Unknown

Dataset Information

0

TrkB Agonist LM22A-4 Increases Oligodendroglial Populations During Myelin Repair in the Corpus Callosum.


ABSTRACT: The neurotrophin, brain-derived neurotrophic factor (BDNF) promotes central nervous system (CNS) myelination during development and after injury. This is achieved via activation of oligodendrocyte-expressed tropomyosin-related kinase (Trk) B receptors. However, while administration of BDNF has shown beneficial effects, BDNF itself has a poor pharmacokinetic profile. Here, we compare two TrkB-targeted BDNF-mimetics, the structural-mimetic, tricyclic dimeric peptide-6 (TDP6) and the non-peptide small molecule TrkB agonist LM22A-4 in a cuprizone model of central demyelination in female mice. Both mimetics promoted remyelination, increasing myelin sheath thickness and oligodendrocyte densities after 1-week recovery. Importantly, LM22A-4 exerts these effects in an oligodendroglial TrkB-dependent manner. However, analysis of TrkB signaling by LM22A-4 suggests rather than direct activation of TrkB, LM22A-4 exerts its effects via indirect transactivation of Trk receptors. Overall, these studies support the therapeutic strategy to selectively targeting TrkB activation to promote remyelination in the brain.

SUBMITTER: Nguyen HTH 

PROVIDER: S-EPMC6718610 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

TrkB Agonist LM22A-4 Increases Oligodendroglial Populations During Myelin Repair in the Corpus Callosum.

Nguyen Huynh T H HTH   Wood Rhiannon J RJ   Prawdiuk Alexa R AR   Furness Sebastian G B SGB   Xiao Junhua J   Murray Simon S SS   Fletcher Jessica L JL  

Frontiers in molecular neuroscience 20190827


The neurotrophin, brain-derived neurotrophic factor (BDNF) promotes central nervous system (CNS) myelination during development and after injury. This is achieved <i>via</i> activation of oligodendrocyte-expressed tropomyosin-related kinase (Trk) B receptors. However, while administration of BDNF has shown beneficial effects, BDNF itself has a poor pharmacokinetic profile. Here, we compare two TrkB-targeted BDNF-mimetics, the structural-mimetic, tricyclic dimeric peptide-6 (TDP6) and the non-pep  ...[more]

Similar Datasets

| S-EPMC7992919 | biostudies-literature
2017-03-29 | PXD005271 | Pride
| S-EPMC5368975 | biostudies-literature
| S-EPMC7970057 | biostudies-literature
| S-EPMC4510539 | biostudies-literature
| S-EPMC8565522 | biostudies-literature
| S-EPMC7906774 | biostudies-literature
2014-06-05 | PXD000547 | Pride
| S-EPMC8253780 | biostudies-literature
| S-EPMC7145428 | biostudies-literature